When administered to mice with an established (around 200 mm3) B16F10-mCherry-OVA tumour, QX-314 still reduced tumour growth and preserved the anti-tumour capacity of CD8+ T cells (Extended Data Fig. 8k–r), suggesting that it could be used as a therapeutic agent in cancer. This evidence concerns the gene CD8A and cancer.